Advertisement

 

 

Efficacy of a specific polyclonal equine F(ab’)2 against avian influenza (H5N1) in ferrets: synergy with oseltamivir.

Efficacy of a specific polyclonal equine F(ab’)2 against avian influenza (H5N1) in ferrets: synergy with oseltamivir.
Author Information (click to view)

Herbreteau CH, Denizot M, Lowther S, Riddell S, Frazer L, Haining J, Arkinstall R, Payne J, Harper J, Johnson D, Pasquier A, Middleton D, Saluzzo JF,


Herbreteau CH, Denizot M, Lowther S, Riddell S, Frazer L, Haining J, Arkinstall R, Payne J, Harper J, Johnson D, Pasquier A, Middleton D, Saluzzo JF, (click to view)

Herbreteau CH, Denizot M, Lowther S, Riddell S, Frazer L, Haining J, Arkinstall R, Payne J, Harper J, Johnson D, Pasquier A, Middleton D, Saluzzo JF,

Advertisement
Share on FacebookTweet about this on TwitterShare on LinkedIn

Immunotherapy 2016 07 058(9) 1021-32 doi 10.2217/imt-2016-0062

Abstract
AIM
Current therapies against avian influenza (H5N1) provide limited clinical benefit. FBF-001 is a highly purified equine polyclonal immunoglobulin fragment against H5N1.

METHODS
Using a ferret model of severe acute H5N1 infection, we assessed FBF-001 when administered on the same day or 1 day after viral challenge, in comparison with oseltamivir therapy.

RESULTS
Untreated animals died 2-3 days after challenge. FBF-001 prevented most severe illness and reduced nasal viral load, with best efficacy when administered on the day of viral challenge. Oseltamivir and FBF-001 had synergistic impact on survival.

CONCLUSION
FBF-001 prevented severe consequences of lethal H5N1 challenge in ferrets by controlling viral replication, an effect synergistic to oseltamivir. FBF-001 has recently been granted EMA orphan drug status.

Submit a Comment

Your email address will not be published. Required fields are marked *

five × five =

[ HIDE/SHOW ]